Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...